Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $71.4286.

HROW has been the subject of several recent research reports. Zacks Research upgraded Harrow from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. LADENBURG THALM/SH SH raised their target price on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. B. Riley reaffirmed a “buy” rating and set a $74.00 price target (up previously from $70.00) on shares of Harrow in a report on Wednesday, October 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a research note on Tuesday, November 11th. Finally, HC Wainwright raised their price objective on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th.

Harrow Stock Down 1.9%

HROW opened at $42.98 on Friday. The firm’s 50 day simple moving average is $46.41 and its two-hundred day simple moving average is $41.47. The company has a market capitalization of $1.59 billion, a PE ratio of -429.76 and a beta of 0.02. Harrow has a 1-year low of $20.85 and a 1-year high of $54.85. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The firm had revenue of $71.64 million during the quarter, compared to the consensus estimate of $73.70 million. As a group, equities analysts forecast that Harrow will post -0.53 EPS for the current year.

Hedge Funds Weigh In On Harrow

A number of hedge funds have recently made changes to their positions in HROW. Raymond James Financial Inc. bought a new stake in Harrow during the 2nd quarter valued at approximately $48,000. State of Alaska Department of Revenue purchased a new stake in Harrow during the 3rd quarter valued at approximately $83,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after buying an additional 2,615 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in shares of Harrow by 848.2% in the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after buying an additional 1,934 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.